Patent details

LUC00280 Product Name: Padcev - enfortumab vedotin

Basic Information

Publication number:
LUC00280
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP118313451
Legal Status:
Inactive
Application number:
LUC00280
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/21/1615
Marketing Authorization Type:
Marketing Authorization Date:
19/04/2022
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
06/10/2022
First Marketing Authorization date:
19/04/2022
Grant date:
12/05/2025
Activation date:
Publication date:
06/10/2022
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
29/09/2036
SPC Extension Expiration:
29/09/2036
Rejection date:
Withdrawal date:

Owner

From:
06/10/2022
 
 

Name:
AGENSYS, INC.
Address:
1 Astellas Way,, 60062, Northbrook, IL, United States (US)

Name:
SEAGEN INC.
Address:
21823 30th Drive, S.E., 98021, Bothell, WA , United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
06/10/2022
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

Bulletin Heading:
SPC1
Bulletin edition number:
2022/12
Publication date:
08/11/2022
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
30/09/2031
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
06/10/2022 Application Form 3
06/10/2022 General Document 4
06/10/2022 General Document 1
06/10/2022 MA publication 11
06/10/2022 Marketing authorization 3
06/10/2022 Summary of the product caracteristics 43
06/10/2022 Outgoing Correspondence 1
06/10/2022 Publication 1
12/05/2025 Publication 1
12/05/2025 Certificate 1
12/05/2025 Outgoing Correspondence 1